医薬品リファレンス
Cangrelor
Cangrelor is a medicine in the class cardiovascular. It is used for coronary artery stent thrombosis.
- 薬効分類: Cardiovascular
- 効能・効果: coronary artery stent thrombosis
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Cardiovascular
- 一般的な剤形
- 注射剤
- 一般的な規格
- 50 mg
- 既知の相互作用
- 3 (重大: 2 · 中等度: 1)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation; binds selectively and reversibly to the P2Y12 receptor.
成人の通常用量（添付文書の要約）
Adjunct to PCI: 30 mcg/kg IV bolus before PCI, followed immediately by 4 mcg/kg/min IV infusion for at least 2 hours or the duration of PCI, whichever is longer.
妊娠と授乳
- 妊娠
- Unknown No human data. Animal studies showed no malformations, but fetal growth retardation and increased abortion/intrauterine losses occurred at higher doses. May increase maternal bleeding during labor and delivery.
- 授乳
- Unknown No data on presence in milk; exposure in the breastfed infant is expected to be very low due to short half-life.
報告されている副作用
- Bleeding
- Dyspnea
- Hypersensitivity reactions (anaphylaxis, bronchospasm, angioedema, stridor)
- Worsening renal function in severe renal impairment
禁忌
- Significant active bleeding.
- Known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
注意が必要な方
- Bleeding risk: P2Y12 inhibitors including cangrelor increase bleeding risk; bleeding events of all severities were more common than with clopidogrel. No antiplatelet effect after an hour once discontinued.
- Neuraxial blockade is not advised during use because of potential spinal hematoma risk; discontinue 1 hour before labor, delivery, or neuraxial blockade when possible.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (3)
- Cangrelor + Clopidogrel Major
- Cangrelor + Prasugrel Major
- Cangrelor + Warfarin Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Cangrelorの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Cangrelor used for?
Cangrelor is a medicine in the class cardiovascular. It is used for Coronary artery stent thrombosis, Myocardial infarction.
What side effects have been reported with Cangrelor?
Bleeding, Dyspnea, Hypersensitivity reactions (anaphylaxis, bronchospasm, angioedema, stridor), Worsening renal function in severe renal impairment.
Can Cangrelor be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. No human data. Animal studies showed no malformations, but fetal growth retardation and increased abortion/intrauterine losses occurred at higher doses. May increase maternal bleeding during labor and delivery. Breastfeeding: Unknown. No data on presence in milk; exposure in the breastfed infant is expected to be very low due to short half-life.
What does Cangrelor interact with?
MediHelp lists 3 known interactions for Cangrelor. Major: 2 · Moderate: 1. The most serious include Clopidogrel, Prasugrel, Warfarin.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
